Inventor · disambiguated record
Shaharyar Khan
Also filed as: KHAN SHAHARYAR · KHAN SHAHARYAR M
13 granted patents·18 pending applications·84 citations·filing 2002–2025
89Inventor score
Top patents by PatentIndex Score
31 records- 0193US8133733B2Nonviral vectors for delivering polynucleotides to target tissuesKHAN SHAHARYAR·Filed 2007·Granted Mar 13, 2012·37 cites·10 claims
- 0290US8062891B2Nonviral vectors for delivering polynucleotides to plantsKHAN SHAHARYAR·Filed 2007·Granted Nov 22, 2011·13 cites·7 claims
- 0384US8039587B2Methods and compositions for delivering polynucleotidesGENCIA CORP·Filed 2004·Granted Oct 18, 2011·22 cites·6 claims
- 0481US8470972B2Nonviral vectors for delivering polynucleotides to plantsKHAN SHAHARYAR·Filed 2011·Granted Jun 25, 2013·2 cites·15 claims
- 0579US8541550B2Methods and compositions for delivering polynucleotidesKHAN SHAHARYAR·Filed 2011·Granted Sep 24, 2013·4 cites·9 claims
- 0674US8927691B2Transducible polypeptides for modifying metabolismKHAN SHAHARYAR·Filed 2012·Granted Jan 6, 2015·2 cites·5 claims
- 0773US8507277B2Nonviral vectors for delivering polynucleotidesKHAN SHAHARYAR·Filed 2006·Granted Aug 13, 2013·1 cites·4 claims
- 0872US10618875B2Phenyl derivativesRIVUS PHARMACEUTICALS INC·Filed 2018·Granted Apr 14, 2020·1 cites·13 claims
- 0972US2025214944A1Novel Phenyl DerivativesRIVUS PHARMACEUTICALS INC·Filed 2025·Application pending·0 cites
- 1071US8906390B2Synthetic lipid rafts and methods of useKHAN SHAHARYAR·Filed 2007·Granted Dec 9, 2014·1 cites·9 claims
- 1169US2022048865A1Novel Phenyl DerivativesRIVUS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1267US9434753B2Modified creatine compoundsGENCIA CORP·Filed 2012·Granted Sep 6, 2016·1 cites·18 claims
- 1367US2009208478A1Transducible polypeptides for modifying metabolismGENCIA CORP·Filed 2009·Application pending·0 cites
- 1466US2021238144A1Phenyl DerivativesRIVUS PHARMACEUTICALS INC·Filed 2021·Application pending·0 cites
- 1564US2020399225A1Novel Phenyl DerivativesRIVUS PHARMACEUTICALS INC·Filed 2020·Application pending·0 cites
- 1659US9707244B2Compositions and methods for treating conditions that affect epidermisGENCIA CORP·Filed 2014·Granted Jul 18, 2017·0 cites·17 claims
- 1759US2010179106A1Mitochondrial compositions and uses thereofGENCIA CORP·Filed 2008·Application pending·0 cites
- 1858US2014113853A1Transducible Polypeptides for Modifying MetabolismGENCIA CORP·Filed 2013·Application pending·0 cites
- 1956US7741112B2Vector mediated organelle transfectionUNIV VIRGINIA·Filed 2002·Granted Jun 22, 2010·0 cites·4 claims
- 2056US2009123468A1Transducible polypeptides for modifying metabolismGENCIA CORP·Filed 2008·Application pending·0 cites
- 2153US8952133B2Nonviral vectors for delivering polynucleotides to target tissueKHAN SHAHARYAR·Filed 2012·Granted Feb 10, 2015·0 cites·13 claims
- 2253US2014045798A1Mitochondrial compositions and uses thereofGENCIA CORP·Filed 2013·Application pending·0 cites
- 2352US2013072462A1Mitochondrial Compositions and Uses ThereofKHAN SHAHARYAR·Filed 2012·Application pending·0 cites
- 2450US2007196334A1Modified vectors for organelle transfectionGENCIA CORP·Filed 2004·Application pending·0 cites
- 2549US2018000846A1Compositions and Methods for Treating Conditions That Affect EpidermisGENCIA CORP·Filed 2017·Application pending·0 cites
- 2648US2015283233A1Compositions and Methods for Enhancing Immune ResponsesGENCIA CORP·Filed 2013·Application pending·0 cites
- 2748US2016038565A1Methods of Mitigating Side Effects of Radiation Exposure and ChemotherapyGENCIA CORP·Filed 2013·Application pending·0 cites
- 2846US2025134865A1Methods of weight loss in a subject with elevated hba1cRIVUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 2946US2025134864A1Methods of weight loss and preserving skeletal muscle massRIVUS PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 3044US2007141009A1Sirna mediated post-transriptional gene silencing of genes involved in alopeciaKHAN SHAHARYAR·Filed 2004·Application pending·0 cites
- 3144US2025177353A1Methods of treating mitochondria-related disordersRIVUS PHARMACEUTICALS INC·Filed 2022·Application pending·0 cites
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →